Amgen Aranesp Price Is In Middle Of Procrit Range; Reimbursement Likely
Executive Summary
Amgen is launching the anemia agent Aranesp at a price falling in the middle of the range for Johnson & Johnson's erythropoietin brand Procrit.
You may also be interested in...
Aranesp Oncology Label Includes Emphasis On Longer Half-Life Than Procrit
Aranesp labeling for chemotherapy-induced anemia includes increased emphasis on the product's less frequent dosing than epoetin alfa (J&J's Procrit)
Aranesp Oncology Label Includes Emphasis On Longer Half-Life Than Procrit
Aranesp labeling for chemotherapy-induced anemia includes increased emphasis on the product's less frequent dosing than epoetin alfa (J&J's Procrit)
Amgen Ends Praecis Plenaxis Collaboration After FDA Requests More Studies
Praecis is planning additional studies on the prostate cancer treatment Plenaxis (abarelix) to evaluate switching non-responders to alternate therapies.